Abrocitinib Reduces Skin Pain in Adolescent and Adult Patients With Moderate-to-Severe Atopic Dermatitis

Main Article Content

Jacob P. Thyssen
Anthony Bewley
Sonja Ständer
Carla Castro
Laurent Misery
Brian S. Kim
Pinaki Biswas
Gary L. Chan
Daniela E. Myers
Melissa Watkins
Justine Alderfer
Erman Güler
Jonathan I. Silverberg


Abrocitinib, JAK1 inhibitor, Moderate-to-Severe Atopic Dermatitis, Skin Pain


1. Vakharia PP et al. Ann Allergy Asthma Immunol. 2017;119:548-552.e3

2. Cibinqo (abrocitinib). Prescribing information. Pfizer Labs; January 2022.

3. Cibinqo (abrocitinib). Summary of product characteristics. European Medicines Agency; December 17, 2021.

4. Hall R et al. Dermatol Ther (Heidelb). 2021;11:221-233.

5. Thyssen J et al. Presented at: 3rd Annual Revolutionizing Atopic Dermatitis Virtual Conference; December 11-13, 2021. Abstract 639.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 > >>